Amarin About
Amarin Amarin is a biotechnology neuroscience company
focused on developing novel drugs for the treatment of central nervous system
disorders. Amarin’s leading pipeline product, MiraxionTM, is in development
for a number of therapeutic indications including Huntington’s disease ("HD")
and treatment-unresponsive depression. Amarin is listed on the Nasdaq small cap
market (ticker: AMRN), has headquarters in London and a research and development
facility in Stirling, Scotland. Miraxion for Huntington's
Disease and unrepsonsive depression More
on Amarin
Key
Statistics for Amarin
Basic
Chart for Amarin